<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239083</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080ATR01</org_study_id>
    <nct_id>NCT00239083</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients</brief_title>
  <official_title>Phase IV Study of Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The aim of MYFORMS is to assess efficacy and safety on clinical outcomes of EC-MPS in&#xD;
      combination with Cyclosporine microemulsion (CsA-ME) in kidney transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient and graft survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>acute rejection incidence</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>graft function</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>safety</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>influence of demographic characteristics, transplant-related variables, medical conditions and post-transplantation complications on the main clinical outcomes, according to the immunosuppressive regimen used.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>EC-MPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-Coated Mycophenolate Sodium (EC-MPS)</intervention_name>
    <arm_group_label>EC-MPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        De Novo-Inclusion criteria&#xD;
&#xD;
          1. Males and females aged 6 years or over.&#xD;
&#xD;
          2. Recipients of cadaveric, living unrelated or living related kidney transplant, treated&#xD;
             with CsA-Me, with or without corticosteroids, as primary immunosuppression.&#xD;
&#xD;
        Maintenance-Inclusion criteria&#xD;
&#xD;
          1. Males and females aged 6 years or over.&#xD;
&#xD;
          2. Recipients of first or secondary cadaveric, living related or unrelated donor kidney&#xD;
             transplant.&#xD;
&#xD;
          3. Patients currently receiving CsA-ME with or without Mycophenolate mofetil (MMF) or&#xD;
             azathioprine, with or without corticosteroids as part of their immunosuppressive&#xD;
             regimen for at least 3 months prior to Screening.&#xD;
&#xD;
          4. Patients in a stable condition in terms of graft function (serum creatinine not above&#xD;
             2.3 mg/dL (=204 µmol/L) at screening and at baseline, or not increased by more than&#xD;
             20% at baseline compared to values obtained at screening), no change of immune&#xD;
             suppressive regimen due to graft malfunction, and any known clinically significant&#xD;
             physical and/or laboratory changes for at least 2 months prior to enrollment.&#xD;
&#xD;
        De Novo and Maintenance-Exclusion Criteria&#xD;
&#xD;
          1. Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any&#xD;
             organ other than kidney.&#xD;
&#xD;
          2. Patients with any known hypersensitivity to MPA, EC-MPS or other components of the&#xD;
             formulation (e.g. lactose).&#xD;
&#xD;
          3. Patients with thrombocytopenia (&lt; 75,000/mm3), with an absolute neutrophil count of &lt;&#xD;
             1,500/mm3, and/or leukocytopenia (&lt; 2,500/mm3), and/or hemoglobin &lt; 6 g/dL at&#xD;
             Screening or Baseline.&#xD;
&#xD;
          4. Patients with a history of malignancy within the last five years, except excised&#xD;
             squamous or basal cell carcinoma of the skin.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Nart A, Sipahi S, Aykas A, Uslu A, Hoşcoşkun C, Toz H. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients. Transplant Proc. 2008 Jan-Feb;40(1):189-92. doi: 10.1016/j.transproceed.2007.11.066.</citation>
    <PMID>18261583</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2005</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>MYFORMS, Kidney Transplantation, Enteric-Coated Mycophenolate Sodium (EC-MPS), Cyclosporine microemulsion (CsA-ME)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

